QPPV.COM

Drug-Induced Neurotoxicity: Neurological Safety Assessment in Clinical Development and Pharmacovigilance

Understand how drug-induced neurotoxicity is recognised and medically evaluated, how neurological phenotypes are characterised, how nonclinical and clinical findings are integrated, and how potential neurological safety signals are assessed in clinical development and pharmacovigilance.

Audio Lesson 16 min
Knowledge Assessment Test your understanding of this article. Take the assessment →

Drug-Induced Neurotoxicity: Neurological Safety Assessment in Clinical Development and Pharmacovigilance

Introduction

The nervous system is a critical target of drug safety assessment because adverse effects on the brain, spinal cord, peripheral nerves and autonomic nervous system can produce substantial morbidity and, in some circumstances, life-threatening outcomes.

Neurological toxicity can present in many different ways.

A drug may cause:

Unlike Hy's Law for hepatotoxicity, there is no single laboratory pattern that defines serious drug-induced neurotoxicity.

The nervous system is anatomically and functionally complex, and different toxic mechanisms produce different clinical phenotypes.

A useful neurological safety assessment therefore begins with a different question:

What neurological phenotype has occurred, and what is the most plausible explanation for it?

The assessment then integrates:

ICH S7A identifies the central nervous system as part of the safety-pharmacology core battery and describes assessment of motor activity, behavioural changes, coordination, sensory and motor reflex responses and body temperature. The guideline also allows follow-up studies when pharmacology, nonclinical findings, clinical trials, pharmacovigilance or literature raise additional concerns. [1]

Drug-induced neurotoxicity should therefore be understood as a multidimensional safety problem, rather than as a single adverse-event term.

Learning Objectives

After reading this article, the reader should be able to:

Understanding Drug-Induced Neurotoxicity

What Is Drug-Induced Neurotoxicity?

Drug-induced neurotoxicity refers to an adverse effect of a medicinal product on the structure or function of the nervous system.

The effect may involve:

Neurotoxicity may be direct.

For example, a drug may interfere with neuronal ion channels or neurotransmitter systems.

It may also be indirect.

For example, a drug may cause severe electrolyte disturbance, hypoglycaemia, hypoxia, hypotension or hepatic dysfunction, with secondary neurological consequences.

This distinction is important in pharmacovigilance.

A patient who develops confusion during treatment may have drug-induced encephalopathy, but may instead have:

The clinical phenotype must therefore be established before causality is assigned.

Functional Versus Structural Neurotoxicity

Neurological toxicity can be broadly considered along two overlapping dimensions.

Functional toxicity alters neurological function without necessarily producing an immediately demonstrable structural lesion.

Examples include:

Structural toxicity involves demonstrable injury to nervous-system tissue.

Examples may include:

The distinction is not absolute.

Functional abnormalities may precede structural injury, and structural injury may initially present through functional symptoms.

The safety assessment should therefore avoid assuming that a normal MRI or other investigation excludes clinically important neurotoxicity.

Why the Nervous System Is Vulnerable

The nervous system has several characteristics that can make it susceptible to drug effects.

Neurons depend on:

The blood-brain barrier also creates a specialised environment for CNS exposure.

A drug's neurological effects may therefore depend on:

Peripheral nerves have different vulnerabilities.

Long axons require substantial intracellular transport and energy production. Some drugs preferentially affect axons, myelin or neuronal transport mechanisms.

The safety physician should therefore consider the pharmacological mechanism rather than treating all neurological events as one category.

Major Neurological Toxicity Phenotypes

Seizures

Seizures are among the most clinically important neurological adverse events.

A seizure may result from:

The assessment should establish whether the event was actually a seizure.

Possible evidence includes:

A reported "seizure" in a spontaneous case may represent syncope, psychogenic nonepileptic seizure, movement disorder or another event.

The preferred approach is therefore to reconstruct the event rather than accept the reported diagnosis without review.

Encephalopathy and Altered Mental Status

Drug-induced encephalopathy may present with:

The differential diagnosis is broad.

The reviewer should consider:

A medication may contribute without being the sole cause.

For example, several sedating medicines may combine to produce an adverse effect that would not have occurred with any one medicine alone.

Peripheral Neuropathy

Peripheral neuropathy may be predominantly:

Clinical manifestations may include:

The pattern matters.

A length-dependent symmetrical sensory neuropathy has a different differential diagnosis from an acute asymmetric motor neuropathy.

FDA clinical-development guidance for chemotherapy-induced peripheral neuropathy illustrates the importance of prospectively characterising neuropathy in clinical development rather than relying only on spontaneous adverse-event terminology. [2]

Ataxia and Coordination Disorders

Ataxia may involve:

Potential drug-related causes include effects on:

The reviewer should distinguish true cerebellar ataxia from:

This distinction can materially change causality assessment.

Movement Disorders

Drug-induced movement disorders include:

Many arise from altered neurotransmission, particularly dopaminergic pathways, but other mechanisms may also be involved.

The timing of onset and relationship to dose are often informative.

The reviewer should consider whether the phenotype represents:

Cognitive and Psychiatric Effects

Some medicinal products can produce:

These events can be difficult to attribute because the background incidence is high in many populations.

The assessment should consider:

The safety physician should avoid equating temporal association with causality.

Neuroinflammation and Demyelination

Some drug-related neurological syndromes involve inflammatory or immune-mediated mechanisms.

Potential manifestations include:

Evaluation may require:

The diagnostic approach should be tailored to the phenotype.

The objective is to establish whether there is evidence of an inflammatory or structural neurological process rather than simply assigning a broad adverse-event term.

Neurological Examination and Clinical Assessment

Why the Neurological Examination Matters

The neurological examination can provide information that laboratory testing cannot.

Depending on the presentation, assessment may include:

Changes should be compared with baseline where baseline assessment is available.

A clinically meaningful change may be more informative than an isolated abnormal finding.

Baseline Neurological Status

Baseline assessment is particularly important in populations with substantial pre-existing neurological disease.

A trial subject may already have:

Without adequate baseline information, a later event may be incorrectly attributed to treatment.

The reviewer should therefore establish whether the finding is:

Temporal Relationship

Timing should be reconstructed precisely.

Relevant dates include:

Different neurological phenotypes may have different latency patterns.

An event occurring immediately after administration may suggest a different mechanism from neuropathy developing progressively over months.

Temporal plausibility is supportive but not sufficient for causality.

Seizure Risk

Some drugs can increase neuronal excitability or otherwise lower the seizure threshold.

Potential mechanisms include:

Risk may increase in patients with:

The presence of a risk factor does not establish causality, but it changes the background probability.

EEG

Electroencephalography may help evaluate suspected seizures.

However, a normal routine EEG does not necessarily exclude epilepsy or a drug-related seizure.

Interpretation depends on:

Continuous EEG may be appropriate in selected hospitalised patients with persistent altered consciousness or suspected non-convulsive seizures.

The safety reviewer should therefore interpret EEG in clinical context.

Recurrent Seizures and Seriousness

A single seizure may have a different clinical significance from:

The seriousness assessment should therefore include the clinical consequences rather than relying solely on the preferred adverse-event term.

Central Neurotoxicity

Sedation and CNS Depression

CNS depression can range from mild somnolence to profound loss of consciousness.

The assessment should consider:

In some cases the neurological event may be secondary to pharmacodynamic interaction rather than direct neurotoxicity.

Delirium

Delirium is characterised by an acute disturbance in attention and cognition with a fluctuating course.

Potential contributors include:

A drug may be a precipitating factor rather than the sole cause.

The medical review should therefore examine the entire clinical context.

Cognitive Effects

Cognitive adverse effects can be subtle.

Potential domains include:

Where cognitive effects are important to the therapeutic area, validated assessments may provide more useful information than spontaneous symptom descriptions.

Changes should ideally be interpreted against baseline and comparator data.

Peripheral Neuropathy

Clinical Characterisation

The assessment of suspected drug-induced peripheral neuropathy should establish:

The reviewer should also consider common alternative causes such as:

Nerve Conduction Studies

Nerve conduction studies can help distinguish:

They may also help establish severity and progression.

However, not every neuropathy requires electrophysiological testing.

The investigation should be driven by clinical circumstances.

Reversibility

Some drug-related neuropathies improve after treatment interruption, while others may persist.

Persistence does not exclude drug causality.

Similarly, improvement after withdrawal supports but does not prove causality.

The reviewer should consider the expected natural history of the specific neurological syndrome.

Neuroimaging and EEG

MRI

Magnetic resonance imaging may be useful when evaluating:

A normal MRI does not exclude all forms of neurotoxicity.

Functional neurological effects may occur without visible structural abnormalities.

CT

Computed tomography can be useful in acute settings, particularly when rapidly excluding:

MRI may provide greater sensitivity for many neurological disorders.

The choice should therefore be determined clinically.

EEG and Other Neurophysiology

EEG is particularly useful for seizure assessment.

Electromyography and nerve conduction studies can assist in peripheral neuropathy.

Evoked potentials may be useful in selected neurological conditions.

These investigations should be interpreted as components of the clinical assessment rather than automatic proof of drug causality.

Neurological Biomarkers

Why Biomarkers Are Challenging

There is no universally accepted biomarker equivalent to ALT or creatinine for general drug-induced neurotoxicity.

Candidate markers may reflect:

Examples investigated in research include:

Their usefulness depends on the specific neurological phenotype and assay context.

FDA's neurotoxicology programme specifically identifies development and qualification of quantitative biomarkers as an area of regulatory science research. [3]

Neurofilament Light Chain

Neurofilament light chain is released following injury to axons.

It can be measured in:

An increase may indicate neuronal or axonal injury.

However, it is not specific for drug toxicity.

Other neurological diseases and injuries can also increase neurofilament concentrations.

Therefore:

a biomarker of neuronal injury is not automatically a biomarker of drug causality.

Biomarkers and Clinical Interpretation

Biomarkers should be interpreted together with:

No biomarker should be used as a substitute for clinical diagnosis unless its intended use and qualification support that application.

Nonclinical Neurotoxicity Assessment

ICH S7A

ICH S7A places CNS assessment within the safety-pharmacology core battery.

The guideline identifies assessment of:

Functional observation batteries or comparable approaches may be used. [1]

The objective is to identify potentially adverse pharmacodynamic effects on vital functions before and during clinical development.

Follow-Up Studies

Additional nonclinical assessment may be warranted when:

ICH S7A specifically describes follow-up and supplemental safety-pharmacology studies when concerns arise from pharmacology, nonclinical studies, clinical trials, pharmacovigilance or literature. [1]

Translational Interpretation

Nonclinical findings should not be treated as direct predictions of human neurological toxicity.

The reviewer should consider:

The most useful interpretation connects nonclinical findings with human exposure and phenotype.

Drug-Induced Neurotoxicity in Clinical Development

Individual-Subject Review

Individual subjects should receive medical review when they develop:

The reviewer should reconstruct the case chronologically.

Population-Level Review

Clinical-development teams may examine:

The purpose is to determine whether there is a consistent treatment-related pattern.

Treatment Versus Control

Comparator data are particularly valuable for neurological events because many have substantial background incidence.

The assessment should consider:

An imbalance may warrant further investigation but does not automatically establish causality.

Exposure-Response

Exposure-response analysis can strengthen a drug-related hypothesis.

Relevant observations may include:

However, absence of an exposure-response relationship does not exclude causality.

Idiosyncratic neurological reactions may not show a simple concentration relationship.

Post-Marketing Pharmacovigilance

Sources of Neurological Safety Information

Post-marketing neurological information may arise from:

Each source has different strengths and limitations.

Spontaneous reports can identify rare neurological events but may lack detailed neurological examination or diagnostic testing.

Case-Level Medical Review

A potential neurological safety case should be reconstructed chronologically.

The reviewer should establish:

The objective is to establish the most plausible clinical diagnosis before assigning causality.

Signal Detection

Potential population-level signals may involve:

Signal detection should lead to clinical evaluation.

A statistical association or disproportionate reporting pattern does not independently establish that the medicinal product caused the neurological event.

FDA's modern safety-monitoring infrastructure also illustrates the increasing importance of systematic analysis of adverse-event data at scale. [4]

Aggregate Assessment

An aggregate neurological safety assessment may consider:

The strength of the signal depends on the consistency and quality of the evidence.

Worked Examples

Example 1: Seizure After Treatment Initiation

A patient without a previous seizure disorder develops a generalised seizure several weeks after starting a new medicine.

The reviewer identifies:

The event warrants evaluation as a potential drug-related seizure.

However, the conclusion should remain proportionate to the evidence.

A single case may establish a serious adverse event requiring investigation without establishing a population-level neurotoxicity signal.

Example 2: Confusion in a Patient Receiving Multiple Medicines

A patient develops acute confusion after initiation of a new medicine.

The patient is also receiving:

Laboratory testing shows worsening renal function.

The drug may contribute to CNS depression, but several alternative explanations exist.

The reviewer should consider:

The appropriate conclusion may therefore be that the event is multifactorial rather than attributing it automatically to the newly introduced medicine.

Example 3: Progressive Peripheral Neuropathy

A patient develops gradually progressive distal sensory symptoms during prolonged treatment.

The neurological examination demonstrates:

The patient has no diabetes and no other obvious explanation.

The temporal relationship, phenotype and absence of competing causes increase the plausibility of drug-related neuropathy.

Nerve conduction studies may further characterise the pattern.

The case should then be assessed against known class effects and the broader clinical-development or post-marketing experience.

Example 4: Encephalopathy With a Competing Cause

A patient receiving a new medicine develops confusion.

At the same time:

The neurological event may therefore be secondary to systemic disease rather than direct CNS toxicity.

The correct pharmacovigilance approach is to document the competing causes rather than classify the event as direct drug-induced neurotoxicity solely because it occurred after treatment.

Example 5: Neuroinflammatory Syndrome

A patient develops:

MRI demonstrates inflammatory changes and cerebrospinal-fluid testing supports an inflammatory CNS process.

The reviewer should consider:

If the product has a known immune-mediated mechanism and the timing is compatible, the case may represent an important emerging safety signal.

The diagnosis should nevertheless be established independently of the causality conclusion.

Limitations of Neurological Safety Assessment

No Single Neurological Biomarker

There is no universal laboratory test that identifies all forms of neurotoxicity.

Different biomarkers measure different biological processes.

A normal biomarker therefore cannot exclude every form of neurological toxicity.

High Background Incidence

Neurological symptoms are common in the general population.

Examples include:

This creates substantial background noise in clinical trials and spontaneous-reporting systems.

The specificity of the phenotype therefore matters.

Underlying Disease

Many patients receiving CNS-active or systemic therapies already have neurological disease.

Disease progression can mimic drug toxicity.

This is particularly important in:

Baseline information is therefore critical.

Diagnostic Uncertainty

Spontaneous reports may contain terms such as:

These terms do not necessarily represent definitive clinical diagnoses.

Medical review should distinguish reported symptoms from medically established phenotypes.

Multiple Mechanisms May Coexist

A drug may produce neurological effects through more than one mechanism.

For example:

The most plausible explanation may therefore be multifactorial.

Practical Medical Review Framework

Step-by-Step Neurological Safety Review

A structured review may proceed through the following sequence:

  1. Confirm the reported neurological event.
  2. Establish the clinical phenotype.
  3. Determine whether the finding is new or pre-existing.
  4. Establish treatment exposure and timing.
  5. Review dose and pharmacokinetics.
  6. Review concomitant medicines.
  7. Assess renal and hepatic function where relevant.
  8. Review metabolic and infectious causes.
  9. Review neurological examination findings.
  10. Review EEG, imaging and other investigations where available.
  11. Assess the severity and clinical consequences.
  12. Assess dechallenge.
  13. Assess rechallenge where applicable.
  14. Consider the known pharmacology of the product.
  15. Consider nonclinical neurological findings.
  16. Determine whether similar cases exist.
  17. Assess alternative explanations.
  18. Determine the most likely clinical diagnosis.
  19. Assess causality.
  20. Document the medical rationale.

This sequence prevents the adverse-event term from replacing clinical reasoning.

Medical Documentation

A medically important neurological safety assessment should document, as appropriate:

The documentation should allow another qualified reviewer to reconstruct the reasoning.

Pharmacovigilance and Inspection Considerations

Inspection Perspective

During an inspection, an organisation should be able to demonstrate that important neurological safety signals were identified, evaluated and followed appropriately.

An inspector may reasonably expect to understand:

The objective is not merely to demonstrate that neurological adverse events were coded.

The organisation should be able to demonstrate the medical reasoning behind their evaluation.

Common Documentation Weaknesses

Potential weaknesses include:

Good documentation should allow independent reconstruction of the clinical reasoning.

Common Mistakes in Neurotoxicity Assessment

Common errors include:

The most important correction is to move from event terminology to clinical phenotype.

What an Experienced Safety Physician Looks For

An experienced safety physician does not begin with:

"Is this a neurotoxicity case?"

The first questions are:

Only after these questions have been addressed should the reviewer decide whether the medicinal product is the most plausible cause.

This approach prevents neurological terminology from becoming a substitute for medical assessment.

Neurological Safety Compared With Liver, Kidney and Cardiac Safety

Different organ systems illustrate different approaches to safety assessment.

Organ system Important safety approach
Liver ALT, AST, ALP, bilirubin, Hy's Law, eDISH
Kidney creatinine, eGFR, urine output, proteinuria, renal injury biomarkers
Heart QT/QTc, ECG, troponin, ventricular function, arrhythmias
Nervous system neurological phenotype, examination, EEG, imaging, electrophysiology, selected biomarkers

The difference is important.

Liver safety has relatively well-established biochemical patterns.

Kidney safety combines functional and structural indicators.

Cardiac safety combines electrophysiology, biomarkers, imaging and clinical events.

Neurological safety is particularly dependent on clinical phenotype and specialised functional assessment.

There is therefore no single universal numerical neurological equivalent of Hy's Law.

The strongest assessment integrates:

phenotype + chronology + exposure + examination + investigations + competing causes + population evidence.

Key Takeaways

Drug-induced neurotoxicity is a broad safety concept involving the central, peripheral and autonomic nervous systems.

There is no single laboratory threshold that defines clinically important neurotoxicity.

The first step in assessment is to establish the neurological phenotype.

Important phenotypes include:

Neurological examination, EEG, imaging, electrophysiology and selected biomarkers can provide complementary information.

ICH S7A places CNS assessment within the safety-pharmacology core battery and supports assessment of motor activity, behaviour, coordination, reflexes and body temperature. [1]

Nonclinical findings should be integrated with human exposure and clinical observations rather than treated as independent proof of human neurotoxicity.

Post-marketing assessment requires careful distinction between reported neurological symptoms and confirmed clinical diagnoses.

The most important principle is:

Drug-induced neurotoxicity is a phenotype-driven safety problem requiring clinical interpretation, not a laboratory threshold that produces an automatic diagnosis.

References

  1. International Council for Harmonisation. S7A Safety Pharmacology Studies for Human Pharmaceuticals. 2001.

  2. U.S. Food and Drug Administration. Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology. Draft Guidance for Industry. January 2025.

  3. U.S. Food and Drug Administration. NCTR Division of Neurotoxicology. Center for Food Safety and Applied Nutrition / National Center for Toxicological Research.

  4. U.S. Food and Drug Administration. FDA Adverse Event Monitoring System (AEMS). 2026.

  5. U.S. Food and Drug Administration. Redbook 2000: IV.C.10. Neurotoxicity Studies. July 2000.

  6. U.S. Food and Drug Administration. Redbook 2000: IV.B.1. General Guidelines for Designing and Conducting Toxicity Studies.

  7. U.S. Food and Drug Administration. Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development: Guidance for Industry. October 2024.

Revision History

Related Articles

Drug-Induced Cardiac Toxicity: Cardiovascular Safety Assessment in Clinical Development and Pharmacovigilance

Understand how potential drug-induced cardiac toxicity is identified and medically evaluated, how ICH E14 and S7B support assessment of QT/QTc and proarrhythmic risk, and how cardiovascular safety signals are assessed across clinical development and pharmacovigilance.

Drug-Induced Hematologic Toxicity: Hematologic Safety Assessment in Clinical Development and Pharmacovigilance

Understand how drug-induced hematologic toxicity is recognised and medically evaluated, how cytopenias are characterised by lineage, severity and mechanism, and how hematologic safety signals are assessed across clinical development and pharmacovigilance.

Drug-Induced Kidney Injury: Renal Safety Assessment in Clinical Development and Pharmacovigilance

Understand how drug-induced kidney injury is identified and medically evaluated, why kidney function and kidney injury are not the same, how renal biomarkers support clinical-trial safety assessment, and how pharmacovigilance teams evaluate potential nephrotoxicity.